Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder

A significant body of evidence documented that the orbitofrontal cortex (OFC) and the head of caudate nucleus are involved in the mediation of obsessive-compulsive disorder (OCD) symptoms. Potent serotonin (5-HT) reuptake inhibitors (SRIs) are the only antidepressant agents thus far shown to be effective in the treatment of OCD. The present review summarizes information on 5-HT release and the adaptive changes in pre- and postsynaptic 5-HT receptors sensitivity induced by SRI treatment in rat and guinea pig structures involved in OCD. It emphasizes that the time course for the occurrence of increased 5-HT release and terminal 5-HT1D desensitization is congruent with the delayed therapeutic response to SRI in OCD. In addition, a greater dose of SRI inducing a greater degree of reuptake inhibition may play an essential role in this phenomenon. This is consistent with the common clinical observation that high doses of SRIs are sometimes necessary to obtain an anti-OCD effect, and with the results of some fixed-dose double blind trials showing a dose-dependent therapeutic effect of SRIs. It is hypothesized that enhanced 5-HT release in the OFC is mediated by the activation of normosensitive postsynaptic 5-HT2-like receptors and underlies the therapeutic action of SRI in OCD. This is supported by the beneficial effect of some hallucinogens with 5-HT2 agonistic properties in obtaining a more rapid therapeutic response. Finally, based on this knowledge, new strategies aimed at producing more rapid, effective and safe anti-OCD drugs, such as a selective action on terminal 5-HT1D receptors, on 5-HT2 receptors as well as on the glutamate system, are discussed.

[1]  G. Chouinard,et al.  Fluoxetine in the treatment of obsessive compulsive disorder , 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  C. Montigny,et al.  Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[3]  N. Alpert,et al.  Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. , 1994, Archives of general psychiatry.

[4]  D. Rosenberg,et al.  Brain anatomy and chemistry may predict treatment response in paediatric obsessive--compulsive disorder. , 2001, The international journal of neuropsychopharmacology.

[5]  C. de Montigny,et al.  Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. , 1986, The Journal of pharmacology and experimental therapeutics.

[6]  P. Blier,et al.  Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration. , 1996, The Journal of pharmacology and experimental therapeutics.

[7]  C. Montigny,et al.  Current advances and trends in the treatment of depression. , 1994, Trends in pharmacological sciences.

[8]  C. de Montigny,et al.  Differential Effect of Gepirone on Presynaptic and Postsynaptic Serotonin Receptors: Single‐Cell Recording Studies , 1990, Journal of clinical psychopharmacology.

[9]  T. Insel,et al.  Obsessive-compulsive disorder and serotonin: Is there a connection? , 1985, Biological Psychiatry.

[10]  C. de Montigny,et al.  Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1A Receptors , 1998, The Journal of Neuroscience.

[11]  E. Hollander,et al.  Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. , 2004, The Journal of clinical psychiatry.

[12]  P. Blier,et al.  Functional characterization of 5‐HT1D autoreceptors on the modulation of 5‐HT release in guinea‐pig mesencephalic raphe, hippocampus and frontal cortex , 1996, British journal of pharmacology.

[13]  P. Blier,et al.  Effect of repeated electroconvulsive shocks on serotonergic neurons. , 1992, European journal of pharmacology.

[14]  D. Beattie,et al.  The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan. , 1995, European journal of pharmacology.

[15]  T. Nordahl,et al.  Cerebral glucose metabolic rates in obsessive compulsive disorder. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[16]  S. Montgomery,et al.  Fluvoxamine in the treatment of obsessive compulsive disorder , 1992, International clinical psychopharmacology.

[17]  C. Montigny,et al.  Increased Tonic Activation of Rat Forebrain 5-HT1A Receptors by Lithium Addition to Antidepressant Treatments , 2000, Neuropsychopharmacology.

[18]  J. Rapoport,et al.  Relief of obsessive-compulsive symptoms by LSD and psilocin. , 1987, The American journal of psychiatry.

[19]  M Briley,et al.  Serotonin autoreceptor subsensitivity and antidepressant activity. , 1990, European journal of pharmacology.

[20]  L. D. van de Kar,et al.  Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. , 1999, The Journal of pharmacology and experimental therapeutics.

[21]  M. Hamon,et al.  Pharmacological and Physicochemical Properties of Pre‐Versus Postsynaptic 5‐Hydroxytryptamine1A Receptor Binding Sites in the Rat Brain: A Quantitative Autoradiographic Study , 1992, Journal of neurochemistry.

[22]  M. Dallman,et al.  Compulsive behavior in the 5-HT2C receptor knockout mouse , 2003, Physiology & Behavior.

[23]  J. Rapoport,et al.  Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. , 1989, Archives of general psychiatry.

[24]  J. Rapoport,et al.  A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. , 1991, Archives of general psychiatry.

[25]  R. Swinson,et al.  Sertraline and Fluoxetine Treatment of Obsessive-Compulsive Disorder: Results of a Double-Blind, 6-Month Treatment Study , 2002, Journal of clinical psychopharmacology.

[26]  P. Blier,et al.  Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive–compulsive disorder , 1999, Biological Psychiatry.

[27]  Frank H. Burton,et al.  A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry , 2002, Molecular Psychiatry.

[28]  C. Montigny.  Electroconvulsive shock treatments enhance responsiveness of forebrain neurons to serotonin. , 1984 .

[29]  A. Rush,et al.  A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. , 1994, Archives of general psychiatry.

[30]  P Pietrini,et al.  Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. , 1992, Archives of general psychiatry.

[31]  S. Taylor,et al.  Deep brain stimulation for refractory obsessive-compulsive disorder , 2005, Biological Psychiatry.

[32]  Michael E Phelps,et al.  FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder , 1998, Psychiatry Research: Neuroimaging.

[33]  N. Fineberg,et al.  Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder , 1992, International clinical psychopharmacology.

[34]  Yves Chaput,et al.  Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[35]  P. Delgado,et al.  Hallucinogen-induced relief of obsessions and compulsions. , 1997, The American journal of psychiatry.

[36]  C. de Montigny,et al.  Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone. , 1993, The Journal of pharmacology and experimental therapeutics.

[37]  J. Palacios,et al.  5-HT1D receptors in guinea-pig and pigeon brain , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  P. Blier,et al.  Effect of atypical antipsychotic drugs on 5-HT2 receptors in the rat orbito-frontal cortex: an in vivo electrophysiological study , 1999, Psychopharmacology.

[39]  P. Blier,et al.  In Vivo Electrophysiological Characterization of 5-HT Receptors in the Guinea Pig Head of Caudate Nucleus and Orbitofrontal Cortex , 1997, Neuropharmacology.

[40]  W. Goodman,et al.  Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. , 1989, Archives of general psychiatry.

[41]  L. Baxter,et al.  Neuroimaging studies of obsessive compulsive disorder. , 1992, The Psychiatric clinics of North America.

[42]  D. Rosenberg,et al.  Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study , 2004, Psychopharmacology.

[43]  H. Nicolini,et al.  A family-based association study of the 5-HT-1Dβ receptor gene in obsessive-compulsive disorder , 2004 .

[44]  David Goldman,et al.  5-HT2A promoter polymorphism −1438G/A, anorexia nervosa, and obsessive-compulsive disorder , 1998, The Lancet.

[45]  H. V. Van Tol,et al.  Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. , 1990, The Journal of biological chemistry.

[46]  L. D. van de Kar,et al.  Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. , 1996, The Journal of pharmacology and experimental therapeutics.

[47]  L. Tecott,et al.  In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[48]  C. Montigny,et al.  Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[49]  P. Blier,et al.  Modulation of 5‐HT release in the guinea‐pig brain following long‐term administration of antidepressant drugs , 1994, British journal of pharmacology.

[50]  H. Westenberg,et al.  Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder , 1998, Psychopharmacology.

[51]  H. Westenberg,et al.  A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. , 2004, The Journal of clinical psychiatry.

[52]  D. Murphy,et al.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. , 1990, Archives of general psychiatry.

[53]  K. Lesch,et al.  Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder , 2005, Psychopharmacology.

[54]  C. Montigny,et al.  Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  L. Koran,et al.  Sumatriptan, 5-HT1D receptors and obsessive-compulsive disorder , 2001, European Neuropsychopharmacology.

[56]  J. Krystal,et al.  Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. , 1990, Archives of general psychiatry.

[57]  P. Blier,et al.  Alteration of Serotonin Release in the Guinea Pig Orbito-Frontal Cortex by Selective Serotonin Reuptake Inhibitors , 1995, Neuropsychopharmacology.

[58]  C. McDougle,et al.  Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. , 1993, The American journal of psychiatry.

[59]  D. Murphy,et al.  A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. , 1992, Journal of clinical psychopharmacology.

[60]  H. Nicolini,et al.  DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive disorder. , 1996, Molecular psychiatry.

[61]  P. Blier,et al.  Enhancing action of LSD on neuronal responsiveness to serotonin in a brain structure involved in obsessive-compulsive disorder. , 2003, The international journal of neuropsychopharmacology.

[62]  P. Blier,et al.  Responsiveness of 5-HT(1A) and 5-HT2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. , 2005, Journal of psychiatry & neuroscience : JPN.

[63]  S. Mitchell,et al.  The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. , 2004, European journal of pharmacology.

[64]  S. Robson,et al.  The in vivo pharmacological profile of a 5‐HT1 receptor agonist, CP‐122, 288, a selective inhibitor of neurogenic inflammation , 1995, British journal of pharmacology.

[65]  Jeffrey M. Schwartz,et al.  Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder , 1998, British Journal of Psychiatry.

[66]  Claudette Boni,et al.  Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine , 2000, Neuropharmacology.

[67]  C. Montigny,et al.  Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors , 1985, Neuroscience.

[68]  C. McDougle,et al.  Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. , 1997, The American journal of psychiatry.

[69]  Dan J Stein,et al.  Single photon emission computed tomography op the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: Investigating the functional role of the serotonin auto-receptor , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[70]  D. Murphy,et al.  Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients , 1998, Psychopharmacology.

[71]  E. Mundo,et al.  5HT1Dβ Receptor gene implicated in the pathogenesis of Obsessive-Compulsive Disorder: further evidence from a family-based association study , 2002, Molecular Psychiatry.

[72]  D. Murphy,et al.  Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. , 2001, The Journal of pharmacology and experimental therapeutics.

[73]  H. Wikström,et al.  Acute and chronic effects of citalopram on postsynaptic 5‐hydroxytryptamine1A receptor‐mediated feedback: a microdialysis study in the amygdala , 2001, Journal of neurochemistry.

[74]  S. Alborzian,et al.  Localized Orbitofrontal and Subcortical Metabolic Changes and Predictors of Response to Paroxetine Treatment in Obsessive-Compulsive Disorder , 1999, Neuropsychopharmacology.

[75]  J. Krystal,et al.  Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder , 2003, Psychopharmacology.

[76]  L. D. van de Kar,et al.  A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[77]  J. Greist,et al.  Obsessive-Compulsive Disorder , 1989, American family physician.

[78]  C. McDougle,et al.  A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. , 2000, Archives of general psychiatry.

[79]  T. Bourgeron,et al.  Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder , 2004, Neuroreport.

[80]  M. Keshavan,et al.  Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[81]  A. McIntyre,et al.  A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder , 1993, European Neuropsychopharmacology.

[82]  J. Gorman,et al.  SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. , 1999, The Journal of clinical psychiatry.

[83]  D. Rosenberg,et al.  Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[84]  L. Lanfumey,et al.  Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[85]  G C Curtis,et al.  Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. , 1989, The Journal of neuropsychiatry and clinical neurosciences.

[86]  L. Bellodi,et al.  Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study , 2005, European Neuropsychopharmacology.

[87]  G. Pearlson,et al.  Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. , 1991, The American journal of psychiatry.

[88]  D. Middlemiss,et al.  Stereoselective actions of the isomers of metitepine at 5-HT1D receptors in the guinea pig brain , 1993, Neuropharmacology.

[89]  D. Sheehan,et al.  The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder. , 1988, The Journal of clinical psychiatry.

[90]  M. Jenike.  Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. , 1993, Psychopharmacology bulletin.

[91]  S. Mitchell,et al.  LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat. , 2001, European journal of pharmacology.

[92]  K. Hanes.  Serotonin, psilocybin, and body dysmorphic disorder: a case report. , 1996, Journal of clinical psychopharmacology.

[93]  D. Middlemiss,et al.  Metitepine distinguishes two receptors mediating inhibition of [3H]-5-hydroxytryptamine release in guinea pig hippocampus , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[94]  T. Insel,et al.  Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. , 1989, Archives of general psychiatry.

[95]  D. Schoepp.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. , 2001, The Journal of pharmacology and experimental therapeutics.

[96]  J. Mazziotta,et al.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. , 1987, Archives of general psychiatry.

[97]  A. Kablinger,et al.  Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. , 1997, The Journal of clinical psychiatry.

[98]  M. Erdal,et al.  T102C and –1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive–compulsive disorder , 2003, European Psychiatry.

[99]  J. Mendels,et al.  A 1 year double‐blind placebo‐controlled fixed dose study of sertraline in the treatment of obsessive‐compulsive disorder , 1995, International clinical psychopharmacology.

[100]  R. Weizman,et al.  Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways , 2000, European Neuropsychopharmacology.

[101]  K. Denicoff,et al.  An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression , 2005, Biological Psychiatry.